AN UNBIASED VIEW OF NEXTSTAGE-SAGA

Apotex alleged that specific US courtroom judgments and FDA conclusions discriminated towards it, denied it minimum common of procedure and expropriated its expense in pravastatin. Damages sought: US£eight million.In January 2011, just after protracted proceedings, the tribunal dismissed the producer's declare on jurisdictional grounds and dismiss